Nisa Investment Advisors
VRCA icon

Nisa Investment Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Nisa Investment Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-142
Closed -$612 – 3098
2025
Q3 		$612 Sell
142
-1
-0.7% -$6 ﹤0.01% 2821
2025
Q2 		$759 Buy
+143
New +$769 ﹤0.01% 2793
2025
Q1 		– Sell
-34
Closed -$235 – 3063
2024
Q4 		$235 Buy
34
+26
+325% +$286 ﹤0.01% 2922
2024
Q3 		$109 Buy
8
+5
+167% +$225 ﹤0.01% 2901
2024
Q2 		$248 Buy
+3
New +$230 ﹤0.01% 2791
2022
Q1 		– Sell
-310
Closed -$25K – 2406
2021
Q4 		$25K Sell
310
-140
-31% -$15.9K ﹤0.01% 1885
2021
Q3 		$56 Hold
450
– – ﹤0.01% 1913
2021
Q2 		$51 Buy
+450
New +$54.5K ﹤0.01% 1939

Other funds holding VRCA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nisa Investment Advisors's VRCA Position: Q4 2025 in Review

Nisa Investment Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q4 2025, closing a stake of 142 shares — an estimated $612 sold.

Nisa Investment Advisors first reported a position in VRCA in Q2 2021 and held it in 8 quarters. The position peaked at $25K in Q4 2021. 50 funds tracked by Wall St. Rank hold VRCA as of Q4 2025.

  • Nisa Investment Advisors reported no remaining Verrica Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 142 Verrica Pharmaceuticals shares in Q4 2025, an estimated $612.
  • Nisa Investment Advisors first reported a position in Verrica Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Nisa Investment Advisors's Verrica Pharmaceuticals position peaked at $25K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2025.

Based on Nisa Investment Advisors's 13F filing for Q4 2025, filed 15 Jan 2026.